Tofacitnib for the Treatment of Alopecia Areata and Variants

Alopecia Areata (AA) Clinical Trial

Official title: Tofacitnib for the Treatment of Alopecia Areata and Variants

Status Completed

Clinical Trial Summary

The purpose of this study is to investigate the ability of tofacitinib citrate, a Janus kinase inhibitor, to generate hair regrowth in patients with moderate to severe alopecia areata and its variants.

Clinical Trial Description

This study is an open-label pilot study. Participants will be treated with oral tofacitinib for a maximum of 5 months. Participants will be evaluated at 3 months after completion of therapy to evaluate for durability of response, late response and/or late adverse effects. ;

Related Conditions & MeSH terms

• Alopecia
• Alopecia Areata
• Alopecia Areata (AA)
• Alopecia Totalis (AT)
• Alopecia Universalis (AU)

• NCT number: NCT02197455
• Study type: Interventional
• Source: Yale University
• Status: Completed
• Phase: Phase 2
• Start date: July 2014
• Completion date: July 2015